uniQure N.V. (NASDAQ:QURE) Stock Has Average Target Price of $53.25

Key Points

• Analysts hold a Moderate Buy consensus on uniQure, with 12 buy ratings, three holds, one sell, and one strong buy among 17 firms. The average 12-month price target is $53.25 versus a recent share price of $22.72.
• Recent analyst views were mixed but generally constructive: UBS raised its target to $48, Wolfe Research set a $65 target with an outperform rating, while Goldman Sachs cut its target to $31 and maintained a neutral rating.
• uniQure reported a quarterly loss of $1.22 per share, worse than the expected $0.82 loss, despite revenue of $5.84 million exceeding estimates. Institutional investors and hedge funds own approximately 78.83% of the company’s stock.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $53.25.

A number of research firms recently issued reports on QURE. The Goldman Sachs Group reduced their target price on uniQure from $46.00 to $31.00 and set a "neutral" rating on the stock in a research note on Wednesday, September 30th. UBS Group reiterated a "buy" rating and set a $48.00 target price (up from $27.00) on shares of uniQure in a report on Thursday, October 15th. Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, September 5th. Wolfe Research raised uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target for the company in a report on Wednesday, July 29th. Finally, HC Wainwright reissued a "buy" rating on shares of uniQure in a report on Tuesday, September 29th.

uniQure Stock Up 2.3%

Shares of NASDAQ QURE opened at $22.72 on Wednesday. uniQure has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a market capitalization of $1.58 billion, a PE ratio of -5.67 and a beta of 1.06. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The firm's 50-day moving average is $38.34 and its two-hundred day moving average is $34.02.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the prior year, the company earned ($0.69) earnings per share. Equities analysts anticipate that uniQure will post -3.82 EPS for the current fiscal year.

Institutional Trading of uniQure

A number of large investors have recently made changes to their positions in QURE. Hennion & Walsh Asset Management Inc. boosted its stake in shares of uniQure by 107.3% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company's stock worth $6,546,000 after purchasing an additional 73,566 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of uniQure by 26.0% during the first quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company's stock worth $1,763,000 after buying an additional 22,248 shares in the last quarter. Kalehua Capital Management LLC acquired a new position in shares of uniQure in the first quarter valued at approximately $4,760,000. Orbimed Advisors LLC raised its position in shares of uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock valued at $34,926,000 after buying an additional 1,398,749 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of uniQure by 249.9% in the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company's stock valued at $23,653,000 after buying an additional 366,781 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure's best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.